Everyday Health on MSN
Is It Safe for Men With Prostate Cancer to Exercise?
Men with prostate cancer can safely exercise, benefiting from reduced treatment side effects, improved mental health, and ...
As this year's awareness month comes to a close, Taub informs patients of the most common warning signs and symptoms of the disease, as well as explains the standard methods for diagnosing prostate ...
Prostate cancer incidence in the US shows a concerning rise, particularly in advanced stages. While early prostate cancer ...
May 4, 2010 (Barcelona, Spain) — Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, ...
3don MSN
Unfolded protein response pathway offers new targets to treat bone weakness in cancer patients
Before a chain of amino acids can become an active and useful protein, it must be processed and folded into the appropriate ...
Patients with prostate cancer receiving ADT who are vitamin D deficient may receive the most bone density benefits from high-dose vitamin D. Vitamin D supplements demonstrated significant benefits in ...
Please provide your email address to receive an email when new articles are posted on . Men without bone pain at diagnosis achieved longer PFS and OS. Bone pain at diagnosis should be a factor for ...
Hormone-suppressing drugs, increasingly used to treat prostate cancer, make men so prone to broken bones that the risks of the treatment may outweigh the benefits in those whose cancer was caught ...
Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...
Prostate cancer, traditionally seen in older men, is increasingly diagnosed in younger males under 30, presenting unique ...
Doctors explain how to protect yourself against prostate cancer, common symptoms of prostate cancer, when to get screened, ...
GE HealthCare strengthens its radiopharmaceutical portfolio by licensing Lantheus' PSMA PET imaging agent, PYLARIFY, for commercialization in Japan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results